Jefferson study shows women with inherited breast cancer gene at greater risk for recurrence and new tumors

The results pose new questions regarding treatment options for women

For many women under 40 with breast cancer, surgery to remove the cancerous lump and accompanying radiation seem the best way to get rid of the disease and preserve the natural breast. But for women who carry a damaged version of BRCA1 or BRCA2, genes predisposing them to breast cancer, such treatment may not be enough. Researchers at Jefferson Medical College have found that such women have a greater risk of either relapsing or developing new tumors years later than those women who receive a lumpectomy and radiation therapy but don't carry one of these genes.

As a result, says Bruce Turner, M.D., Ph.D., assistant professor of radiation oncology at Thomas Jefferson University in Philadelphia and a member of Jefferson's Kimmel Cancer Center, who led the work, women and physicians may want to rethink their treatment options.

"These findings suggest that a woman who has a mutation in BRCA1 or BRCA2 who is treated with breast-conserving therapy not only has a high risk of local recurrence--40 percent according to our study--but also a high risk of developing breast cancer in the other breast as well," Dr. Turner says.

"Our data suggest that breast-conserving therapy may not be the most optimal treatment for breast cancer patients with BRCA1 or BRCA2 mutations who want to reduce the risk of locally recurrent breast cancer."

Dr. Turner and colleagues at Yale University and Myriad Genetics report their findings in the October issue of the Journal of Clinical Oncology.

Of 170,000 new breast cancer cases a year in U.S. women, about 10 percent--17,000 women--are under 40. Some 10 to 15 percent of those women (2,000) carry an altered BRCA1 or BRCA2 gene, and about 70 to 80 percent develop breast cancer.

Dr. Turner and his group wanted to exam

Contact: Steve Benowitz
Thomas Jefferson University

Page: 1 2 3

Related biology news :

1. Jefferson Lab detector technology aids development of cystic fibrosis therapy
2. Jefferson scientists find gene expression pattern may predict behavior of leukemia
3. Jefferson researchers develop microchip to track genetic signature of cancer and normal tissue
4. Jefferson scientists use gene therapy to restore function of damaged heart cells in lab
5. Jefferson researchers uncover biochemical clues to how cells migrate in embryos
6. Jefferson and Brigham and Womens researchers find blue light important for setting biological clock
7. Jefferson Lab experiment generates THz radiation 20,000 times brighter than anyone else
8. Jefferson scientists show neural stem cells can become dopamine-making brain cells in laboratory
9. Jefferson scientists show how collagen gene mutation leads to osteoarthritis
10. Jefferson scientists use gene repair technique to change albino mice hairs to black
11. Jefferson scientists show drug is effective against a Hepatitis C Virus model in the laboratory

Post Your Comments:

(Date:10/26/2015)... LAS VEGAS , Oct. 26, 2015 /PRNewswire/ ... innovator in modern authentication and a founding member of ... of its latest version of the Nok Nok™ S3 ... use standards-based authentication that supports existing and emerging methods ... is ideal for organizations deploying customer-facing applications that require ...
(Date:10/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/zl6bz4/global_voice ) ... Recognition Biometrics Market 2015-2019" report to their offering. ... The global voice recognition biometrics market to grow at ... --> --> The report, Global ... on an in-depth market analysis with inputs from industry ...
(Date:10/22/2015)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... ended September 30, 2015.  --> ... million, a decrease of 33% compared to $6.0 million in the ... 2015 was $2.2 million, or $0.10 per diluted share, which compared ... period a year ago.  --> ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary ... in their initial angel funding process. Now, they are paying it forward to ... early stage investments in the microbiome space. In this, they join other ...
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT ... provide a corporate overview. th Annual Oppenheimer Healthcare ... ET/10:00 a.m. PT . Jim Mazzola , vice president ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. www.aezsinc.com ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
Breaking Biology Technology:
Cached News: